Contact


Dr Aristeidis Chaidos

  • Consultant haematologist and honorary senior lecturer at the Hammersmith Hospital and Imperial College London
  • Expertise in multiple myeloma, lymphoma, and stem cell transplantation

+44 (0)20 3313 4017
a.chaidos@imperial.ac.uk

Areas of research


Myeloma functional heterogeneity in clinical drug resistance and residual disease

Myeloma heterogeneity is the single most important obstacle for optimal therapeutic targeting. A complex genetic landscape, epigenetic mechanisms and cues from tumour microenvironments shape the phenotypic and functional diversification of myeloma cells, which underpins drug resistance and later relapsed disease. Differential transcriptional profiles and gene expression regulatory mechanisms at diagnosis and residual disease provide insight into the biology of drug resistance and reveal novel disease vulnerabilities.

The lab is particularly interested in the biology of BCL2 family proteins. BCL2 inhibition is a promising targeted therapy for t(11;14) myeloma and a unique paradigm of treatment directed by genetics.


Myeloma kidney disease and MGRS

Myeloma kidney disease is a debilitating complication with a profound impact on treatment outcome and survival. Monoclonal Gammopathy of Renal Significance (MGRS) is a rare disease, where small amounts of highly nephrotoxic immunoglobulins or free light chains, produced by otherwise subclinical plasma cell clones, resulting in a bewildering array of renal histopathology and kidney disease.

The lab collaborates with Renal Medicine and Histopathology at Imperial to establish experimental vitro and vivo models of myeloma cast nephropathy and MGRS. We study the proinflammatory and profibrotic pathways induced by the nephrotoxic immunoglobulins and develop novel diagnostics and therapeutic strategies.

Citation

BibTex format

@article{Leung:2019:10.1038/s41581-018-0077-4,
author = {Leung, N and Bridoux, F and Batuman, V and Chaidos, A and Cockwell, P and D'Agati, VD and Dispenzieri, A and Fervenza, FC and Fermand, J-P and Gibbs, S and Gillmore, JD and Herrera, GA and Jaccard, A and Jevremovic, D and Kastritis, E and Kukreti, V and Kyle, RA and Lachmann, HJ and Larsen, CP and Ludwig, H and Markowitz, GS and Merlini, G and Mollee, P and Picken, MM and Rajkumar, VS and Royal, V and Sanders, PW and Sethi, S and Venner, CP and Voorhees, PM and Wechalekar, AD and Weiss, BM and Nasr, SH},
doi = {10.1038/s41581-018-0077-4},
journal = {NATURE REVIEWS NEPHROLOGY},
pages = {45--59},
title = {The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group},
url = {http://dx.doi.org/10.1038/s41581-018-0077-4},
volume = {15},
year = {2019}
}

RIS format (EndNote, RefMan)

TY  - JOUR
AU - Leung,N
AU - Bridoux,F
AU - Batuman,V
AU - Chaidos,A
AU - Cockwell,P
AU - D'Agati,VD
AU - Dispenzieri,A
AU - Fervenza,FC
AU - Fermand,J-P
AU - Gibbs,S
AU - Gillmore,JD
AU - Herrera,GA
AU - Jaccard,A
AU - Jevremovic,D
AU - Kastritis,E
AU - Kukreti,V
AU - Kyle,RA
AU - Lachmann,HJ
AU - Larsen,CP
AU - Ludwig,H
AU - Markowitz,GS
AU - Merlini,G
AU - Mollee,P
AU - Picken,MM
AU - Rajkumar,VS
AU - Royal,V
AU - Sanders,PW
AU - Sethi,S
AU - Venner,CP
AU - Voorhees,PM
AU - Wechalekar,AD
AU - Weiss,BM
AU - Nasr,SH
DO - 10.1038/s41581-018-0077-4
EP - 59
PY - 2019///
SN - 1759-5061
SP - 45
TI - The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group
T2 - NATURE REVIEWS NEPHROLOGY
UR - http://dx.doi.org/10.1038/s41581-018-0077-4
UR - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000453031400010&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
VL - 15
ER -